Cedars-Sinai in Los Angeles is leveraging artificial intelligence to advance the prediction and treatment of pancreatic cancer, introducing the Molecular Twin Precision Oncology Platform. This AI tool excels in identifying biomarkers associated with pancreatic cancer, surpassing standard tests for predicting survival rates.
In a study focused on pancreatic cancers, the AI model, examining 6,363 biological data points, achieved an 87% accuracy in predicting disease survival. This heightened precision is expected to significantly influence treatment decisions and contribute to ongoing research in pancreatic cancer therapies.
Cedars-Sinai envisions broader applications for the Molecular Twin Precision Oncology Platform, with potential use in resource-limited locations. The goal is to extend the tool's reach, enabling its application in areas lacking advanced resources, and facilitating personalised medicine even in locations with limited access to technology.
Dr. Dan Theodorescu, the study's senior author and director of Cedars-Sinai Cancer, anticipates the platform's role in guiding optimal therapy choices for patients while expanding the global accessibility of precision medicine.
Click here to read the original news story.